Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.200
-0.390 (-8.50%)
At close: Mar 6, 2026, 4:00 PM EST
4.160
-0.040 (-0.95%)
After-hours: Mar 6, 2026, 4:04 PM EST

Camp4 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Revenue
3.50.650.35-
Revenue Growth (YoY)
436.50%86.29%--
Cost of Revenue
38.238.8240.6234.1
Gross Profit
-34.7-38.17-40.27-34.1
Selling, General & Admin
17.3614.9211.6110.23
Research & Development
---0.68
Operating Expenses
17.3614.9211.6110.91
Operating Income
-52.06-53.09-51.88-45
Interest Expense
--0.03-0.03-
Interest & Investment Income
2.171.332.810.9
Other Non Operating Income (Expenses)
-30.02-0.01-0.19-0.1
EBT Excluding Unusual Items
-79.91-51.79-49.29-44.19
Asset Writedown
-0.49---
Pretax Income
-80.4-51.79-49.29-44.19
Net Income
-80.4-51.79-49.29-44.19
Net Income to Common
-80.4-51.79-49.29-44.19
Shares Outstanding (Basic)
30500
Shares Outstanding (Diluted)
30500
Shares Change (YoY)
547.76%1087.44%26.47%-
EPS (Basic)
-2.65-11.04-124.79-141.51
EPS (Diluted)
-2.65-11.04-124.79-141.51
Free Cash Flow
-29.83-46-44.83-42.57
Free Cash Flow Per Share
-0.98-9.81-113.51-136.31
Operating Margin
-1488.31%-8142.33%-14822.57%-
Profit Margin
-2298.54%-7943.40%-14083.14%-
Free Cash Flow Margin
-852.83%-7055.67%-12809.43%-
EBITDA
-50.42-51.39-50.2-44.12
D&A For EBITDA
1.641.71.680.88
EBIT
-52.06-53.09-51.88-45
Source: S&P Capital IQ. Standard template. Financial Sources.